Skip to main content
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. — Investor Relations & Filings

Ticker · SANA ISIN · US7995661045 US Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-04-26 Proxy Solicitation & In…
Country US United States of America
Listing US SANA

About Sana Biotechnology, Inc.

https://sana.com/

Sana Biotechnology, Inc. is a company that develops engineered cells as medicines to address the underlying causes of disease. Its core strategy involves two primary platforms: in vivo therapies designed to repair and control genes within a patient's existing cells, and ex vivo therapies that replace missing or damaged cells with new, functional ones. The company utilizes proprietary technologies, such as engineered fusogen proteins, for the targeted delivery of therapeutics. Sana's pipeline is focused on advancing drug candidates for a range of diseases, including diabetes, B-cell cancers, and B-cell related autoimmune disorders.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about the Annual Meeting of Stockholders, including proposals for election of directors and ratification of the independent auditor. It also provides instructions on how to access the full proxy materials and vote. The document is titled 'Proxy Statement' and is clearly related to soliciting shareholder votes for the Annual General Meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is about 4912 characters, which is sufficient to contain substantive proxy solicitation information rather than just a brief announcement. Therefore, the correct classification is PSI with high confidence.
2024-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-26 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 18, 2024, for Sana Biotechnology, Inc. The key content is the resignation of an executive officer, Dr. Douglas Williams, from his position as Executive Vice President and President, Research and Development. This is a clear announcement of a change in senior management. There are no financial statements, earnings data, or other report content. The document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-04-18 English
PRIMARY DOCUMENT
Director's Dealing
2024-04-08 English
3
Director's Dealing
2024-04-08 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-04-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.